# Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

> **NCT02976493** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 500 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT02976493
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2018-06-18
- **Final completion:** 2018-06-18
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02976493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02976493, "Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02976493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*